Shares of Chimerix Inc. undefined shot up 14.4% in premarket trading Monday, after the biopharmaceutical company said it will sell exclusive rights to its...
Shares of Chimerix Inc. shot up 14.4% in premarket trading Monday, after the biopharmaceutical company said it will sell exclusive rights to its smallpox treatment, including Tembexa, to Emergent BioSolutions Inc. for up to $337.5 million plus royalties. Emergent BioSolutions shares were still inactive ahead of the open. Under terms of the deal, Chimerix will receive $225 million and up to $100 million in milestone payments. Chimerix could also receive $12.
shot up 14.4% in premarket trading Monday, after the biopharmaceutical company said it will sell exclusive rights to its smallpox treatment, including Tembexa, to Emergent BioSolutions Inc. for up to $337.5 million plus royalties. Emergent BioSolutions shares were still inactive ahead of the open. Under terms of the deal, Chimerix will receive $225 million and up to $100 million in milestone payments. Chimerix could also receive $12.